In the setting of the acute phase of sepsis, previous studies have also reported the organ-protective effects of systemic administration of beta-blockers, which inhibit sympathetic activity, or alpha-2 agonists, which suppress central sympathetic activation [4, 39]. The gene discussed is PSMA2; the disease is Sepsis.